Cardio Vascular Medical Device Announces Forward Stock Split
December 02 2009 - 7:30AM
PR Newswire (US)
HAIFA, Isreal, December 2 /PRNewswire-FirstCall/ -- Cardio Vascular
Medical Device Corp. (CVSL.OB), a leading developer of advanced
cardiovascular surgery technology, today announced that the
company's Board of Directors approved a one-for-three forward stock
split, in the form of a stock dividend, payable to Cardio Vascular
Medical Device shareholders. The Company will announce in due
course the estimated date the stock split will be payable and the
related record date of the shareholders. The stock split is subject
to FINRA approval. When the forward stock split becomes effective,
shareholders of common stock will receive an additional two shares
for each share held at the record date. "We are pleased to announce
this forward stock split for our shareholders," stated Eli Gonen,
CEO of Cardio Vascular Medical Device Corp. "We expect that the
Board's decision will improve liquidity and trading volume in our
company's stock." About Cardio Vascular Medical Device Cardio
Vascular Medical Device holds a US patent for an innovative
next-generation "steerable guidewire" applicable for all
angioplasty (PCTA) procedures. The technology hinges on a bendable
tip that improves guidewire performance, enables faster procedure
completion, and provides cost benefits for patients as well as
healthcare providers. The guidewire has a unique opportunity to
become the guidewire of choice for surgeons throughout the world.
Learn more about Cardio Vascular Medical Device at:
http://www.cvslmedical.com/ Forward-Looking Statements This letter
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended and Section 21E of
the Securities Exchange Act of 1934, as amended. All
forward-looking statements are inherently uncertain, based on
current expectations and assumptions concerning future events or
future performance of Cardio Vascular Medical Device Corp. and its
technologies. In evaluating such statements, prospective investors
should review carefully various risks and uncertainties identified
in this release, as actual results may differ materially from those
indicated in the forward-looking statements. Cardio Vascular
Medical Device Corp. public filings may be viewed at
http://www.sec.gov/. Contact: Alex Traiman Media Relations
+1-646-863-9729 Asher Zwebner +972-54-464-6363 DATASOURCE: Cardio
Vascular Medical Device Corp. CONTACT: Contact: Alex Traiman, Media
Relations, +1-646-863-9729; Asher Zwebner, +972-54-464-6363,
Copyright